Pre-market: SKIN.SW Cassiopea S.p.A. (SIX) rises 9.85% to CHF35.70 21 Jan 2026: watch volume-led momentum
The SKIN.SW stock moves to CHF35.70 in pre-market trading on 21 Jan 2026, up 9.85% on above-average volume. This early move follows intraday spikes to CHF36.00 with a low of CHF32.00, and volume of 2,756 versus an average 1,818, signalling increased trader interest. We examine why Cassiopea S.p.A. (SKIN.SW) is active today on the SIX exchange, link price drivers to fundamentals, and flag catalysts that could sustain the momentum.
Price action and volume: SKIN.SW stock high-volume mover
SKIN.SW stock opened at CHF32.00 and printed a day high of CHF36.00, a 9.85% intraday rise from the prior close of CHF32.50. Volume of 2,756 is 1.52x the average daily volume of 1,818, confirming this is a genuine high-volume move rather than a thin-market spike.
Fundamentals snapshot: SKIN.SW stock financials and ratios
Cassiopea is a clinical-stage biotech in Healthcare focused on dermatology, listed on SIX (Switzerland) and headquartered in Italy. Key metrics: EPS -1.27, PE -28.13, Price/Book 25.68, 50-day average CHF34.37 and 200-day average CHF37.22. The company shows cash per share CHF0.25 and a current ratio of 1.98, indicating short-term liquidity, while operating cash flow per share is -0.95.
Catalysts and pipeline: SKIN.SW stock news and clinical drivers
Cassiopea’s pipeline includes Winlevi, Breezula (Phase II), CB-06-01 (Phase II) and CB-06-02 (completed Phase II). Positive trial updates, regulatory progress or commercial uptake for Winlevi are typical catalysts that move SKIN.SW stock. We link today’s volume to speculative positioning around clinical or commercial news windows.
Sector context and technicals: SKIN.SW stock versus Healthcare peers
The Healthcare sector average PE is 33.75 and average current ratio 23.49 in our dataset. SKIN.SW’s negative PE and small scale mark it as higher risk relative to larger drugmakers like Roche and Novartis. Technically, the stock sits above its 50-day average (CHF34.37) but below the 200-day average (CHF37.22), suggesting near-term strength inside a longer-term consolidation band.
Meyka grade and model: SKIN.SW stock score and analyst framing
Meyka AI rates SKIN.SW with a score out of 100: 58.42 | Grade: C+ | Suggestion: HOLD. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. The grade reflects modest momentum but ongoing losses (net income per share -1.18) and valuation gaps. Note: grades are informational and not investment advice.
Risks and near-term outlook: SKIN.SW stock risks and opportunities
Primary risks include negative EPS, thin liquidity, and dependency on clinical outcomes; SKIN.SW shows average volume 1,818, and today’s spike to 2,756 can exaggerate moves. Opportunities include positive trial readouts or commercial uptake of Winlevi. Short-term traders should weigh volatility and limited market depth on SIX in CHF.
Final Thoughts
SKIN.SW stock is trading at CHF35.70 pre-market on 21 Jan 2026 after a 9.85% rise and above-average volume of 2,756. Fundamentals show a clinical-stage biotechnology with negative EPS -1.27 and a high price/book 25.68, which underscores valuation risk versus Healthcare peers. Meyka AI’s forecast model projects CHF40.00, implying an upside of 12.05% versus the current CHF35.70; forecasts are model-based projections and not guarantees. Traders should treat today as a volume-led move: confirm any news catalysts, watch liquidity on SIX (Switzerland) and balance pipeline upside against clinical and execution risk. For more background see the company site and our stock page: Cassiopea website and Meyka stock page for SKIN.SW.
FAQs
Why did SKIN.SW stock jump pre-market today?
The pre-market jump to CHF35.70 reflects above-average volume (2,756) and trader interest. Moves often follow speculation around trials or commercial news for Winlevi or Breezula. Confirmed catalysts should appear in official releases or filings.
What are the key financial risks for SKIN.SW stock?
Key risks are negative EPS (-1.27), limited free cash flow, thin liquidity on SIX, and reliance on clinical outcomes. High price/book (25.68) suggests valuation is sensitive to binary news events.
What price target does Meyka AI give for SKIN.SW stock?
Meyka AI’s forecast model projects CHF40.00, implying 12.05% upside from CHF35.70. Forecasts are model-based projections and not guarantees; use them with other research.
Disclaimer:
Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.
